<DOC>
	<DOCNO>NCT02120287</DOCNO>
	<brief_summary>This phase II study usage stereotactic Gamma Knife radiosurgery boost tumor bed border zone conjunction usage bevacizumab .</brief_summary>
	<brief_title>Border Zone Stereotactic Radiosurgery With Bevacizumab Patients With Glioblastoma Multiforme</brief_title>
	<detailed_description>Glioblastoma Multiforme ( GBM ) common primary brain tumor adult . Unfortunately , despite aggressive surgery , radiation therapy ( RT ) chemotherapy , prognosis disease poor . It hypothesis GBM `` local '' disease wherein treatment failure due failure eradicate tumor cell pathways along tumor eventually spread ( `` border zone '' ) . The investigator hypothesize treatment volume escalation successful improve overall survival patient GBM appropriate target precision dose delivery perform single treatment session . The 'border zone ' tumor target SRS ( define combination MRI volume gadolinium enhancement plus 2 cm surround T2 volume ) . This represent volume tumor infiltrate white matter route GBM spread . Bevacizumab , monoclonal antibody vascular endothelial growth factor ( VEGF ) , use safety clinical success concomitant chemotherapy solid tumor , include GBM . The investigator hypothesize combine approach SRS VEGF inhibitor effective strategy GBM bevacizumab maximize effect radiation treat volume potentially reduce radiation toxicity adjacent brain .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>1 . Histologically confirm glioblastoma multiforme , WHO grade IV astrocytoma . 2 . Prior firstline treatment surgery biopsy follow fractionated radiotherapy concurrent temozolomidecontaining chemotherapy require glioblastoma patient . Additional prior chemotherapy allow , without limitation number recurrence . 3 . An interval least 2 month since completion fractionate radiotherapy . 4 . Age &gt; 18 year 5 . Life expectancy least 12 week . 6 . Karnofsky Performance Status score ( KPS ) â‰¥ 60 7 . Documented recurrent disease ; Disease must evaluable , need measurable ; target site SRS need locate previouslyirradiated area . 8 . All patient must restriction obtain MRI without gadolinium contrast . 9 . Adequate bone marrow , hepatic renal function ; BUN &lt; 25 Cr &lt; 1.7 10 . Negative pregnancy test time SRS patient could pregnant . 11 . Willingness forego additional therapy evidence disease progression 1 . General Medical Exclusions : 1 . Current , recent ( within 4 week first infusion study ) , plan participation experimental drug study . 2 . Active malignancy , superficial basal cell superficial squamous ( skin ) cell , carcinoma situ cervix within last 3 year . 3 . Prior radiosurgery 4 . Prior intracavitary irradiation Gliadel wafer . 2 . DiseaseSpecific Exclusions : 1 . Inability comply protocol study procedures 2 . Prior treatment bevacizumab . 3 . Inability undergo MRI without contrast administration . 3 . BevacizumabSpecific Exclusions : 1 . Inadequately controlled hypertension . 2 . Prior history hypertensive crisis hypertensive encephalopathy . 3 . New York Heart Association ( NYHA ) Grade II great congestive heart failure . 4 . History myocardial infarction unstable angina within 6 month prior Day 1 . 5 . History stroke transient ischemic attack within 6 month prior Day 1 . 6 . Significant vascular disease within 6 month prior Day 1 . 7 . History hemoptysiswithin 1 month prior Day 1 . 8 . Evidence bleed diathesis significant coagulopathy 9 . Major surgical procedure , open biopsy , significant traumatic injury within 14 day prior Day 1 anticipation need major non cranial surgical procedure course study . 10 . Core biopsy minor surgical procedure , exclude placement vascular access device , within 7 day prior Day 1 . 11 . History abdominal fistula gastrointestinal perforation within 6 month prior Day 1 . 12 . Serious , nonhealing wound , active ulcer , untreated bone fracture . 13 . Proteinuria 14 . Known hypersensitivity component bevacizumab 15 . Pregnancy ( positive pregnancy test ) lactation . Use effective mean contraception ( men woman ) subject childbearing potential .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Border Zone Stereotactic Radiosurgery</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Recurrent Glioblastoma Multiforme</keyword>
	<keyword>Progressive Glioblastoma Multiforme</keyword>
	<keyword>Magnetic Resonance Spectroscopy</keyword>
	<keyword>Glioblastoma</keyword>
	<keyword>Brain Cancer</keyword>
	<keyword>Brain Tumor</keyword>
	<keyword>Radiosurgery</keyword>
</DOC>